Carboprost
 | |
| Systematic (IUPAC) name | |
|---|---|
| (5Z,9α,11α,13E,15S)-9,11,15-trihydroxy-15- methylprosta-5,13-dien-1-oic acid | |
| Clinical data | |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| MedlinePlus | a600042 |
| |
| |
| Intramuscular | |
| Identifiers | |
58551-69-2  | |
| G02AD04 | |
| PubChem | CID 5281075 |
| DrugBank |
DB00429  |
| ChemSpider |
4444532 |
| UNII |
U4526F86FJ |
| ChEMBL |
CHEMBL1237122 |
| Chemical data | |
| Formula | C21H36O5 |
| 368.508 g/mol | |
|
SMILES
| |
| |
| (what is this?) (verify) | |
Carboprost (INN, trade names for the tromethamine salts Hemabate, Tham) is a synthetic prostaglandin analogue of PGF2α (specifically, it is 15-methyl-PGF2α) with oxytocic properties.
Carboprost induces contractions and can trigger abortion in early pregnancy. It also reduces postpartum bleeding.
Indication
Used in postpartum hemorrhage caused by uterine atony not controlled by other methods. One study has shown that carboprost tromethamine is more effective than oxytocin in preventing postpartum hemorrhage in high-risk patients undergoing caesarian delivery.[1] Carboprost is also used for the termination of pregnancy in the 2nd trimester.[2]
Unlabeled use:
- Hemorrhagic Cystitis
- PID
Contraindication
Contraindicated in severe cardiovascular, renal, and hepatic disease. It is also contraindicated in acute Pelvic Inflammatory Disease. Hypersensitivity to carboprost or any of its components is also a contraindication[2] Exert caution in asthmatic patients.
Precautions
- asthma
- anemia
- jaundice
- diabetes mellitus
- seizure disorders
- past uterine surgery
Adverse Effects
- diarrhea (most common, may be sudden in onset)
- flushing or hot flashes
- fever
- chills
- nausea/vomiting
Storage and Availability
Carboprost is supplied with its salt derivative tromethamine in 1 milliliter ampules containing a 250 microgram/milliliter solution of the active drug. The drug must be refrigerated at a temperature between 2 – 8 degrees Celsius.[2]
References
- ↑ Bai, J; Sun, Q; Zhai, H (2014). "A comparison of oxytocin and carboprost tromethamine in the prevention of postpartum hemorrhage in high-risk patients undergoing cesarean delivery.". Journal of Experimental and Therapeutic Medicine 7 (1): 46–50. doi:10.3892/etm.2013.1379. PMID 24348762.
- ↑ 2.0 2.1 2.2 Hemabate [Package Insert]. New York, NY: Pharmacia and Upjohn Company; 2014.
External links
- Carboprost at the US National Library of Medicine Medical Subject Headings (MeSH)
- Indman P (2004). "Use of carboprost to facilitate hysteroscopic resection of submucous myomas". J Am Assoc Gynecol Laparosc 11 (1): 68–72. doi:10.1016/S1074-3804(05)60014-X. PMID 15104835.
- Vukelić J (2001). "Second trimester pregnancy termination in primigravidas by double application of dinoprostone gel and intramuscular administration of carboprost tromethamine". Med Pregl 54 (1–2): 11–6. PMID 11436877.
- Ippoliti C, Przepiorka D, Mehra R, Neumann J, Wood J, Claxton D, Gajewski J, Khouri I, van Besien K, Andersson B (1995). "Intravesicular carboprost for the treatment of hemorrhagic cystitis after marrow transplantation". Urology 46 (6): 811–5. doi:10.1016/S0090-4295(99)80349-5. PMID 7502421.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||